Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2008 2
2010 2
2011 4
2012 4
2013 7
2014 4
2015 8
2016 8
2017 6
2018 5
2019 9
2020 10
2021 11
2022 9
2023 9
2024 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.
Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, Peng X, Al Janabi H, Huang G, Mittlesteadt J, Cheng M, Bhardwaj A, Ashfeld BL, Kao KR, Maeda DY, Dai X, Wiest O, Blagg BSJ, Lu X, Cheng L, Wan J, Lu X. Zhu Y, et al. Among authors: al janabi h. Sci Immunol. 2023 Mar 17;8(81):eade4656. doi: 10.1126/sciimmunol.ade4656. Epub 2023 Mar 10. Sci Immunol. 2023. PMID: 36897957 Free PMC article.
The need to "carer proof" healthcare decisions.
Al-Janabi H, Nicholls J, Oyebode J. Al-Janabi H, et al. BMJ. 2016 Mar 24;352:i1651. doi: 10.1136/bmj.i1651. BMJ. 2016. PMID: 27013112 No abstract available.
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.
Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C, Junker-Jensen A, Muthana M, Phillips WA, Pearson HB, Taplin ME, Brown JE, Lewis CE. Al-Janabi H, et al. J Immunother Cancer. 2024 Jul 25;12(7):e009368. doi: 10.1136/jitc-2024-009368. J Immunother Cancer. 2024. PMID: 39060021 Free PMC article.
QALYs and carers.
Al-Janabi H, Flynn TN, Coast J. Al-Janabi H, et al. Pharmacoeconomics. 2011 Dec;29(12):1015-23. doi: 10.2165/11593940-000000000-00000. Pharmacoeconomics. 2011. PMID: 22077576
Informal care: choice or constraint?
Al-Janabi H, Carmichael F, Oyebode J. Al-Janabi H, et al. Scand J Caring Sci. 2018 Mar;32(1):157-167. doi: 10.1111/scs.12441. Epub 2017 Apr 12. Scand J Caring Sci. 2018. PMID: 28401583 Free PMC article.
Methodology over metrics: Response to Van Calster et al.
Bunce C, Hewison J, Teare MD, Al-Janabi H, Bonnett L, Hulme C, Kanaan M, Mitchell E, Peters T, Wason J, Williamson P. Bunce C, et al. Among authors: al janabi h. J Clin Epidemiol. 2022 Mar;143:254. doi: 10.1016/j.jclinepi.2021.11.008. Epub 2021 Dec 3. J Clin Epidemiol. 2022. PMID: 34864202 No abstract available.
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.
Henry E, Al-Janabi H, Brouwer W, Cullinan J, Engel L, Griffin S, Hulme C, Kingkaew P, Lloyd A, Payakachat N, Pennington B, Peña-Longobardo LM, Prosser LA, Shah K, Ungar WJ, Wilkinson T, Wittenberg E. Henry E, et al. Among authors: al janabi h. Pharmacoeconomics. 2024 Mar;42(3):343-362. doi: 10.1007/s40273-023-01321-3. Epub 2023 Dec 2. Pharmacoeconomics. 2024. PMID: 38041698 Free PMC article.
83 results